High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation
Open Access
- 18 April 2013
- journal article
- other
- Published by Wiley in British Journal of Haematology
- Vol. 162 (2) , 282-285
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cellsLeukemia Research, 2011
- Hypomethylation of PRAME promoter is associated with poor prognosis in myelodysplastic syndromeBritish Journal of Haematology, 2011
- Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cellsLeukemia, 2010
- Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndromeBlood, 2009
- Elevated expression of the leukemia-associated antigen SSX2IP predicts survival in acute myeloid leukemia patients who lack detectable cytogenetic rearrangementsBlood, 2009
- The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemiaHaematologica, 2008
- Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2in vitroandin vivoLeukemia & Lymphoma, 2008
- Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approachesBlood, 2006
- PRAME mRNA levels in cases with acute leukemia: Clinical importance and future prospectsAmerican Journal of Hematology, 2005
- PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cellsBritish Journal of Haematology, 1998